BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19293192)

  • 1. Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1.
    Wilson TJ; Nannuru KC; Singh RK
    Cancer Res; 2009 Apr; 69(7):3188-95. PubMed ID: 19293192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
    Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2003 Aug; 18(8):1404-18. PubMed ID: 12929930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer.
    Edgington-Mitchell LE; Rautela J; Duivenvoorden HM; Jayatilleke KM; van der Linden WA; Verdoes M; Bogyo M; Parker BS
    Oncotarget; 2015 Sep; 6(29):27008-22. PubMed ID: 26308073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
    Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
    Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-beta signaling and bone destruction.
    Wilson TJ; Nannuru KC; Singh RK
    Mol Cancer Res; 2009 Aug; 7(8):1224-33. PubMed ID: 19671689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation.
    Kamolmatyakul S; Chen W; Li YP
    J Dent Res; 2001 Jan; 80(1):351-5. PubMed ID: 11269728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
    Ono K; Akatsu T; Murakami T; Kitamura R; Yamamoto M; Shinomiya N; Rokutanda M; Sasaki T; Amizuka N; Ozawa H; Nagata N; Kugai N
    J Bone Miner Res; 2002 May; 17(5):774-81. PubMed ID: 12009007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
    Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.
    Min Y; Ren X; Vaught DB; Chen J; Donnelly E; Lynch CC; Lin PC
    Cancer Res; 2010 Apr; 70(7):2819-28. PubMed ID: 20233869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin K is the principal protease in giant cell tumor of bone.
    Lindeman JH; Hanemaaijer R; Mulder A; Dijkstra PD; Szuhai K; Bromme D; Verheijen JH; Hogendoorn PC
    Am J Pathol; 2004 Aug; 165(2):593-600. PubMed ID: 15277232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin K inhibitors as treatment of bone metastasis.
    Le Gall C; Bonnelye E; Clézardin P
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):218-22. PubMed ID: 18685424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta induces osteoclast ruffling and chemotaxis: potential role in osteoclast recruitment.
    Pilkington MF; Sims SM; Dixon SJ
    J Bone Miner Res; 2001 Jul; 16(7):1237-47. PubMed ID: 11450699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin G, a neutrophil-derived serine protease, increases susceptibility of macrophages to acute human immunodeficiency virus type 1 infection.
    Moriuchi H; Moriuchi M; Fauci AS
    J Virol; 2000 Aug; 74(15):6849-55. PubMed ID: 10888624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxin stimulates osteoclast differentiation and activation.
    Ferlin A; Pepe A; Facciolli A; Gianesello L; Foresta C
    Bone; 2010 Feb; 46(2):504-13. PubMed ID: 19833242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism.
    Sivagurunathan S; Pagel CN; Loh LH; Wijeyewickrema LC; Pike RN; Mackie EJ
    J Mol Endocrinol; 2013 Jun; 50(3):347-59. PubMed ID: 23419317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.
    Dodds RA; James IE; Rieman D; Ahern R; Hwang SM; Connor JR; Thompson SD; Veber DF; Drake FH; Holmes S; Lark MW; Gowen M
    J Bone Miner Res; 2001 Mar; 16(3):478-86. PubMed ID: 11277265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.